KR20230082659A - 루푸스에서의 발적의 치료 - Google Patents

루푸스에서의 발적의 치료 Download PDF

Info

Publication number
KR20230082659A
KR20230082659A KR1020237015211A KR20237015211A KR20230082659A KR 20230082659 A KR20230082659 A KR 20230082659A KR 1020237015211 A KR1020237015211 A KR 1020237015211A KR 20237015211 A KR20237015211 A KR 20237015211A KR 20230082659 A KR20230082659 A KR 20230082659A
Authority
KR
South Korea
Prior art keywords
patient
patients
sle
anifrolumab
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015211A
Other languages
English (en)
Korean (ko)
Inventor
루바나 칼리아니
가브리엘 아브레우
라젠드라 툼말라
리처드 푸리
에릭 모란드
안카 아스카나제
에드 바이탈
케네스 칼루니언
카타리나 린드홀름
엠마누엘 마호
크리스티 클레오디스
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20230082659A publication Critical patent/KR20230082659A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
KR1020237015211A 2020-10-08 2021-10-07 루푸스에서의 발적의 치료 Pending KR20230082659A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063089355P 2020-10-08 2020-10-08
US63/089,355 2020-10-08
US202163178748P 2021-04-23 2021-04-23
US63/178,748 2021-04-23
PCT/EP2021/077702 WO2022074123A1 (en) 2020-10-08 2021-10-07 Treatment of flares in lupus

Publications (1)

Publication Number Publication Date
KR20230082659A true KR20230082659A (ko) 2023-06-08

Family

ID=78269610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015211A Pending KR20230082659A (ko) 2020-10-08 2021-10-07 루푸스에서의 발적의 치료

Country Status (11)

Country Link
US (1) US20240026015A1 (https=)
EP (1) EP4225791A1 (https=)
JP (1) JP2023546361A (https=)
KR (1) KR20230082659A (https=)
CN (1) CN116406296A (https=)
AU (1) AU2021356122B2 (https=)
BR (1) BR112023006328A2 (https=)
CA (1) CA3197055A1 (https=)
IL (1) IL301759A (https=)
TW (1) TW202237647A (https=)
WO (1) WO2022074123A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
BR112023021868A2 (pt) * 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
EP4587005A1 (en) 2022-09-14 2025-07-23 Viatris Asia Pacific Pte. Ltd. Sip 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
EP4545090A1 (en) * 2023-10-27 2025-04-30 Universität Leipzig Interferon-a receptor immune modulator for use as a medicament

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035082T2 (en) 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
EP2687232A1 (en) * 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
KR102766960B1 (ko) * 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) * 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病

Also Published As

Publication number Publication date
BR112023006328A2 (pt) 2023-05-09
TW202237647A (zh) 2022-10-01
AU2021356122A1 (en) 2023-06-08
CA3197055A1 (en) 2022-04-14
IL301759A (en) 2023-05-01
CN116406296A (zh) 2023-07-07
US20240026015A1 (en) 2024-01-25
AU2021356122B2 (en) 2026-02-05
WO2022074123A1 (en) 2022-04-14
EP4225791A1 (en) 2023-08-16
JP2023546361A (ja) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7805393B2 (ja) 皮下注射のための抗ｉｆｎａｒ１投薬計画
KR20230082659A (ko) 루푸스에서의 발적의 치료
KR20220099985A (ko) 전신성 홍반성 루푸스에서 i형 인터페론 억제
KR20240000557A (ko) 피부 홍반 루푸스의 치료
KR20240038773A (ko) 루푸스의 치료
KR20240006549A (ko) 전신 홍반성 루푸스 환자에서 1형 인터페론 수용체 스테로이드 절약의 억제제
CN117157099A (zh) 用于皮下注射的抗ifnar1给药方案
EA047082B1 (ru) Схема введения дозы антитела к ifnar 1 для подкожной инъекции
EA052183B1 (ru) Лечение кожной красной волчанки
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection
KR20260013475A (ko) 루푸스의 치료
CN117337305A (zh) 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230503

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240830

Comment text: Request for Examination of Application